Lung Cancer: A Lung Cancer Pill Found to Cut Death Risk by Half in a Major Trial
Impressive outcomes from a lung cancer drug have been reported in recently published research over the weekend. Osimertinib, a tablet, was found to reduce mortality risk in half over a five-year period in patients who had it coupled with surgery. Patients whose tumours have a rather frequent mutation type are the target population for the treatment. Osimertinib is marketed under the trade name Tagrisso and was created by the business AstraZeneca. It belongs to a group of medications that block the EGFR protein, also known as the epidermal growth factor receptor. Normal cells need EGFR, but some malignancies make far larger amounts of it, which promotes their growth. Osimertinib received FDA approval in 2015 to treat advanced non-small cell lung cancers (NSCLCs) with a certain EGFR-related mutation. Since then, AstraZeneca has worked to demonstrate that its medication can effectively treat all of these EGFR-related malignancies. The latest England Journal of Medicine published the...